Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of “Hold” by Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has earned an average recommendation of “Hold” from the six research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $42.20.

A number of brokerages have weighed in on OMCL. Wells Fargo & Company lowered their price objective on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. Barclays assumed coverage on shares of Omnicell in a research report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price target for the company. Finally, Benchmark reduced their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, February 9th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Gotham Asset Management LLC raised its holdings in Omnicell by 4.7% in the 3rd quarter. Gotham Asset Management LLC now owns 8,120 shares of the company’s stock valued at $366,000 after acquiring an additional 368 shares during the last quarter. Martin & Co. Inc. TN raised its holdings in Omnicell by 0.5% in the 3rd quarter. Martin & Co. Inc. TN now owns 95,183 shares of the company’s stock valued at $4,287,000 after acquiring an additional 466 shares during the last quarter. Covestor Ltd raised its holdings in Omnicell by 65.6% in the 3rd quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after acquiring an additional 537 shares during the last quarter. SFE Investment Counsel raised its holdings in Omnicell by 5.3% in the 3rd quarter. SFE Investment Counsel now owns 11,745 shares of the company’s stock valued at $529,000 after acquiring an additional 589 shares during the last quarter. Finally, Summit Creek Advisors LLC grew its stake in shares of Omnicell by 0.4% during the 3rd quarter. Summit Creek Advisors LLC now owns 205,865 shares of the company’s stock valued at $9,272,000 after buying an additional 765 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Up 1.3 %

OMCL opened at $28.18 on Tuesday. The business’s 50-day simple moving average is $27.71 and its 200-day simple moving average is $32.62. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.52. Omnicell has a one year low of $25.69 and a one year high of $77.14. The stock has a market capitalization of $1.29 billion, a P/E ratio of -62.62 and a beta of 0.76.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The firm had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. Analysts anticipate that Omnicell will post 0.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.